MedPath

Evaluation of the Adhesion to the GENEPY Network

Conditions
Hereditary Cancer Syndrome
Hereditary Breast and Ovarian Cancer
Hereditary Colorectal Endometrial Cancer Syndrome
Registration Number
NCT03979612
Lead Sponsor
Institut Claudius Regaud
Brief Summary

In order to best meet the needs of all those affected by the genetic risk of cancer in our region, it is important to identify the factors likely to influence the course leading to the GENEPY surveillance network. The aim of this study is to evaluatie the adhesion to the network of care of people at genetic risk of cancer in Midi-Pyrénées (GENEPY).

Detailed Description

This network has been open since November 2015 for people who are genetically predisposed to breast / ovarian cancer. The extension to digestive pathologies (HNPCC syndrome, PAF) is in progress. It concerns not only the persons carrying a mutation also those belonging to a family without identified mutation but whose risk of predisposition is important.

The GENEPY network is based on a collaboration between oncogenetic consultations in the region and professionals practicing in institutions (private, public) and liberal: general practitioners, gynecologists, radiologists, oncologists, gastroenterologists, psychologists ...

It is therefore a multicentric and multidisciplinary network, which aims to promote the local care of people genetically predisposed (or considered at high risk of genetic predisposition), while ensuring a high level of competence, to guarantee an optimal and equitable care on the whole of Midi Pyrenees.

The diagnosis of a new genetic disease in an individual is likely to have implications for other family members who may themselves be at risk of developing the disease and / or passing it on to their children.

The inclusion of subjects in the GENEPY network follows the genealogical study of a case (index) : relatives are identified as potentially at risk. In accordance with the recommendations, but also generally at the wish of the patients, the index case is then asked to inform its relatives and to propose them to go to an oncogenetic consultation of their choice. If these people reside in the Midi Pyrenees Toulouse oncogenetic consultation is open to them. If following this consultation a mutation is identified or that their genetic risk is considered important, they are proposed to join the GENEPY network for their monitoring.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
450
Inclusion Criteria
  • people with an identified mutation, predisposing to tumors of the breast / ovary or colon / rectum
  • people resident in the Midi-Pyrénées region
Exclusion Criteria
  • people under 18

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proximity to the index case1 day

relationship of the relatives with the index case according to the latter contact

Adhesion to the GENEPY network6 months

Network membership rate : comparison between the number of relatives who received the invitation and the number of them who joined the network.

Age of relatives1 day

Age of the relative of the patient who answered the questionnaire

Place of residence of the relatives1 day

distance from the offer of care and level of deprivation (for the relative of the patient who answered the questionnaire)

Sex of relatives1 day

sex of the relative of the patient who answered the questionnaire

Cancer status Communication1 day

Patient's agreement to communicate about his illness to his relative

Secondary Outcome Measures
NameTimeMethod
Practionners satisfaction1 year

satisfaction of general practitioners (scale of values by questionnaire)

People satisfaction1 year

satisfaction of people who have joined the network (scale of values by questionnaire)

Trial Locations

Locations (1)

Institut Claudius Regaud - IUCT-Oncopole

🇫🇷

Toulouse, Occitanie, France

© Copyright 2025. All Rights Reserved by MedPath